Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs). Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug. Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiod...
Main Authors: | Yoon Ju Choi, Jae-Eon Lee, Hyun Dong Ji, Bo-Ra Lee, Sang Bong Lee, Kil Soo Kim, In-Kyu Lee, Jungwook Chin, Sung Jin Cho, Jaetae Lee, Sang-Woo Lee, Jeoung-Hee Ha, Yong Hyun Jeon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/3/1077 |
Similar Items
-
Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer
by: Lin Liu, et al.
Published: (2017-09-01) -
Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01) -
Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
by: June-Key Chung, et al.
Published: (2014-09-01) -
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
by: Jierui Liu, et al.
Published: (2019-09-01) -
Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)